The effects of frequent nocturnal home hemodialysis: the Frequent Hemodialysis Network Nocturnal Trial  by Rocco, Michael V. et al.
see commentary on page 1018
The effects of frequent nocturnal home hemodialysis:
the Frequent Hemodialysis Network Nocturnal Trial
Michael V. Rocco1, Robert S. Lockridge Jr2, Gerald J. Beck3, Paul W. Eggers4, Jennifer J. Gassman3,
Tom Greene5, Brett Larive3, Christopher T. Chan6, Glenn M. Chertow7,8, Michael Copland9, Christopher D.
Hoy10, Robert M. Lindsay11, Nathan W. Levin12, Daniel B. Ornt13, Andreas Pierratos14, Mary F. Pipkin2,
Sanjay Rajagopalan15, John B. Stokes16, Mark L. Unruh17, Robert A. Star4 and Alan S. Kliger18, and
the Frequent Hemodialysis Network (FHN) Trial Group19
1Medical Center Boulevard, Section on Nephrology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA;
2Lynchburg Nephrology Physicians, University of Virginia, Lynchburg, Virginia, USA; 3Cleveland Clinic Foundation, Cleveland, Ohio, USA;
4National Institutes of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA; 5University of Utah, Salt Lake City, Utah,
USA; 6University Health Network, University of Toronto, Ontario, Canada; 7Stanford University, Palo Alto, California, USA; 8University of
California San Francisco, San Francisco, California, USA; 9University of British Columbia at Vancouver, Vancouver, British Columbia,
Canada; 10Rubin Dialysis Center, Saratoga Springs, New York, USA; 11University of Western Ontario, London, Ontario, Canada; 12Renal
Research Institute, New York City, New York, USA; 13Case Western Reserve University, Cleveland, Ohio, USA; 14Humber River Regional
Hospital, University of Toronto, Weston, Ontario, Canada; 15Ohio State University, Columbus, Ohio, USA; 16University of Iowa and Iowa
City VA Medical Center, Iowa City, Iowa, USA; 17University of Pittsburgh, Pittsburgh, Pennsylvania, USA and 18Hospital of St Raphael,
Yale University, New Haven, Connecticut, USA
Prior small studies have shown multiple benefits of
frequent nocturnal hemodialysis compared to conventional
three times per week treatments. To study this further,
we randomized 87 patients to three times per week
conventional hemodialysis or to nocturnal hemodialysis
six times per week, all with single-use high-flux dialyzers.
The 45 patients in the frequent nocturnal arm had a 1.82-fold
higher mean weekly stdKt/Vurea, a 1.74-fold higher average
number of treatments per week, and a 2.45-fold higher
average weekly treatment time than the 42 patients in the
conventional arm. We did not find a significant effect of
nocturnal hemodialysis for either of the two coprimary
outcomes (death or left ventricular mass (measured by MRI)
with a hazard ratio of 0.68, or of death or RAND Physical
Health Composite with a hazard ratio of 0.91).
Possible explanations for the left ventricular mass result
include limited sample size and patient characteristics.
Secondary outcomes included cognitive performance,
self-reported depression, laboratory markers
of nutrition, mineral metabolism and anemia, blood
pressure and rates of hospitalization, and vascular access
interventions. Patients in the nocturnal arm had improved
control of hyperphosphatemia and hypertension, but
no significant benefit among the other main secondary
outcomes. There was a trend for increased vascular access
events in the nocturnal arm. Thus, we were unable to
demonstrate a definitive benefit of more frequent nocturnal
hemodialysis for either coprimary outcome.
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Patients on maintenance hemodialysis in the United States
have suffered from annual mortality rates of B18–20% for
two decades.1 The National Cooperative Dialysis Study
demonstrated that an insufficient dialysis dose was associated
with a higher hospitalization rate.2 However, the HEMO
study indicated that an increased dose of dialysis provided
during the three times per week hemodialysis did not
significantly improve survival, cardiovascular, or infection-
related hospitalizations3 or improve health-related quality of
life, functional status, or nutritional status.4,5
Investigators have hypothesized that an increased fre-
quency of hemodialysis could lead to improved patient
outcomes, as increased frequency results in both an increased
clearance of solutes and a reduced interdialytic change in
volume. More frequent dialysis can be performed through
either a short daily schedule6 or a longer overnight or
nocturnal schedule. Observational studies7–14 of nocturnal
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hemodialysis performed 5 to 6 nights per week and one
randomized trial15 published after we started have suggested
that frequent nocturnal hemodialysis was associated with
decreased left ventricular (LV) mass,8,15 improved control of
hypertension,8–11,15 a marked increase in phosphorus clear-
ance, often leading to the discontinuation of phosphate
binders,10–12,14,15 and, in some studies, with improved
nutritional status,14 health-related quality of life,11 and sleep
apnea.13 The Frequent Hemodialysis Network (FHN) Noc-
turnal Trial was designed to rigorously compare frequent
nocturnal home hemodialysis six times per week with
conventional three times per week hemodialysis using a
randomized controlled clinical trial design.
RESULTS
Baseline characteristics
A total of 118 patients were enrolled into the trial, and 87
patients were randomized: 42 in the conventional arm and 45
in the frequent nocturnal arm (Figure 1). The baseline
characteristics in Table 1 demonstrate that demographic,
socioeconomic, and medical characteristics were similar
between the two randomized groups.
Adherence to the dialysis prescription
Measurements obtained during monthly kinetic modeling
sessions indicated that 86% of patients in the frequent
nocturnal arm had a delivered mean standard (std)Kt/Vurea of
X4.0, and that 100% of patients in the conventional arm had
a delivered mean stdKt/Vurea ofX2.0. Adherence was defined
a priori as a patient attending at least 80% of dialysis
treatments in a given month. As expected, patients in the
frequent nocturnal arm had lower adherence to the
prescribed dialysis prescription (72.7%) than patients in the
conventional arm (97.6%, Table 2). Nevertheless, frequent
nocturnal arm participants had a 1.82-fold higher mean
weekly stdKt/Vurea, a 1.74-fold higher average number of
treatments per week, a 2.45-fold higher average weekly
treatment time than the conventional arm participants
(Table 2 and Figure 2), as well as a 1.23-fold higher total
weekly ultrafiltration and a 0.74-fold lower interdialytic
normalized weight change. The dialysate concentrations of
potassium and calcium, but not sodium, were higher in the
frequent nocturnal arm compared with the conventional
arm. Finally, the use of the buttonhole technique was
significantly more common in the frequent nocturnal arm
compared with the conventional arm.
Coprimary outcomes
Three patients died (one from air embolism, one from an
epidural hematoma in the frequent nocturnal arm, and one
from ventricular fibrillation in the conventional arm) and five
patients were transplanted (three in the frequent nocturnal
arm; Figure 1). In the frequent nocturnal arm, three patients
had no 12-month LV mass data and three patients had
incomplete data for the baseline to 12-month physical health
composite (PHC) score comparisons; the respective numbers
in the conventional arm were 0 and 1, respectively. Frequent
nocturnal hemodialysis did not yield a statistically significant
improvement for either of the coprimary composite out-
comes (Figures 3a, b, 4a and b).
Main secondary outcomes
The mean difference in the change in LV mass between the
frequent nocturnal and conventional arms was 8.8 g (95%
confidence interval (CI) 21.8 to þ 4.2 g without covariate
adjustment, and was 10.9 g (95% CI 23.7 to þ 1.8 g) after
adjustment for the pre-specified covariates; Table 3 and
Figures 4 and 5). After covariate adjustment, the estimated
treatment effect for the change in LV mass factored by
baseline body surface area was 5.2 g/m2 (95% CI 11.4 to
þ 1.0 g/m2). The mean difference in the change in the PHC
score between the frequent nocturnal and conventional arms
was 1.2 points (95% CI 3.1 to 5.4 points) without covariate
adjustment and was 0.6 points (95% CI 3.4 to 4.7 points)
after covariate adjustment.
Patients in both arms of the trial showed an improvement
in the PHC score from baseline to follow-up, with an average
increase of 2.4 points (95% CI 0.3 to 4.5 points, P¼ 0.02).
Frequent nocturnal dialysis improved control of hyperpho-
sphatemia and hypertension. There were no statistically
significant differences between the study arms for the other
main secondary outcomes (Table 3 and Figure 5). Although
there was no difference in monthly erythropoietin dose
between the two arms, the monthly dose of intravenous iron
Enrollment
Enrolled in baseline (n =118)
Randomized (n=87)
Allocation
Follow-up
Analysis
Analyzed
Lost to follow-up Lost to follow-up
Allocated to frequent nocturnal
(6× per week) hemodialysis (n=45)
Allocated to conventional
(3× per week) hemodialysis (n=42)
Excluded (n=31)
 Patient unwilling or unable to
    receive home dialysis (n=9)
 Home not suitable or monitoring
    not available for dialysis (n=7)
 MRI not obtained (n=3)
 Baseline GFR > 10
    ml/min per 1.73m2  (n=1)
 Other reasons (n=11)
 Transplants (n=2)
 Deaths (n=1)
 Change in LV mass (n=39)
 Change in PHC (n=38)
Analyzed
 Deaths (n=2)
 Change in LV mass (n=37)
 Change in PHC (n=38)
 No end of study LV mass (n=0)
 No end of study PHC (n=1)
 Transplants (n=3)
 No end of study LV mass (n=3)
 No end of study PHC (n=1)
Figure 1 | FHN Nocturnal Trial patient flow. FHN, Frequent
Hemodialysis Network; GFR, glomerular filtration rate; LV, left
ventricular; MRI, magnetic resonance imaging; PHC, physical health
composite.
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Table 1 | Baseline characteristicsa
Factor
All patients
(n=87)
Conventional
hemodialysis (n=42)
Frequent nocturnal
hemodialysis (n=45) P-value
Age (years) 52.8±13.6 54.0±12.9 51.7±14.4 0.48
Female (%) 34.5 33.3 35.6 0.83
Race 0.67
Black (%) 26.4 26.2 26.7
White (%) 55.2 50.0 60.0
Native American, Aboriginal Canadian, Alaskan Native, First Nation (%) 3.4 4.8 2.2
Asian (%) 13.8 16.7 11.1
Native Hawaiian or other Pacific Islander (%) 1.1 2.4 0
Body mass index (kg/m2) 29.0±8.0 28.3±7.8 29.7±8.3 0.67
Weight after HD (kg) 85.5±25.4 83.3±23.8 87.6±27.0 0.43
Anthropometric volume (l) 42.2±9.8 41.6±9.5 42.7±10.0 0.73
Cause of ESRD 0.47
Diabetic nephropathy (%) 34.5 35.7 33.3
Glomerulonephritis (%) 35.6 40.5 31.1
Hypertensive nephrosclerosis (%) 8.0 7.1 8.9
Polycystic kidney disease (%) 21.8 16.7 26.7
ESRD vintage
o1 year (%) 51.7 59.5 44.4 0.38
1 to o2 years (%) 14.9 11.9 17.8
2 to 5 years (%) 14.9 11.9 17.8
45 years (%) 18.4 16.7 20.0
Urine volume (ml) 0.47
o100ml/day 27.6 26.2 28.9
100–499ml/day 20.7 16.7 24.4
500–999ml/day 34.5 38.1 31.1
41000ml/day 17.2 19.1 15.6
Comorbid medical conditions
Hypertension (%) 89.7 90.5 88.9 0.81
Myocardial infarction (%) 10.3 9.5 11.1 0.81
Heart failure (%) 13.8 16.7 11.1 0.45
Atrial fibrillation (%) 6.9 0 13.3 0.014
Peripheral vascular disease (%) 17.2 16.7 17.8 0.89
Abdominal aortic aneurysm repair or bypass grafting (%) 8.0 11.9 4.4 0.20
Stroke (CVA) (%) 2.3 2.4 2.2 0.96
Dementia (%) 0 0 0 —
Tumor without metastases (%) 1.1 0 2.2 0.33
Diabetes and diabetic complications (%) 42.5 42.9 42.2 0.95
Hemiplegia (%) 0 0 0 —
Chronic pulmonary disease (%) 4.6 4.8 4.4 0.94
Moderate-to-severe liver disease (%) 1.1 2.4 0 0.30
Residual kidney function (urea clearance in ml/min) 0.95
Anuric (%) 27.6 26.2 28.9
40–1 (%) 18.4 21.4 15.6
41–3 (%) 34.5 33.3 35.6
43 (%) 19.5 19.0 20.0
Predialysis diastolic blood pressure (mmHg) 81.3±12.1 83.1±13.5 79.6±10.6 0.28
Serum creatinine (mg/dl)b 8.8±3.0 8.9±3.1 8.6±3.0 0.66
Weekly standard Kt/Vurea 2.34±0.34 2.34±0.34 2.38±0.35 0.58
Equilibrated Kt/Vurea 1.38±0.37 1.34±0.30 1.42±0.42 0.33
Dialysis access 0.48
Fistula (%) 47.1 40.5 53.3
Synthetic graft (%) 8.0 9.5 6.7
Catheter (%) 44.8 50.0 40.0
Abbreviations: CVA, cerebrovascular accident; ESRD, end-stage renal disease; HD, hemodialysis.
aShown are either mean±s.d. or percentage for each baseline factor.
bTo convert values for creatinine to mmol/l, multiply by 88.4.
1082 Kidney International (2011) 80, 1080–1091
or ig ina l a r t i c l e MV Rocco et al.: Frequent home nocturnal hemodialysis
was lower in the frequent nocturnal arm compared with
the conventional arm. The rate of the composite outcome
of death or first non-access hospitalization did not differ
significantly between the two groups (hazard ratio¼ 1.33,
95% CI 0.67–2.65).
Complications of therapy
There was a trend toward an increased rate of access
complications in the frequent nocturnal arm, driven by
a higher number of vascular access procedures (Table 4).
A total of 34 vascular access events (17 failures and 17 access
procedures) occurred in the frequent nocturnal arm and 21
events (13 failures and 8 access procedures) in the
conventional arm (P¼ 0.10). The fraction of events affecting
fistulas, grafts, and catheters were 50, 6, and 44% in the
frequent nocturnal arm and 19, 24, and 57% in the
conventional arm. A total of 51% of patients in the frequent
nocturnal arm and 36% of patients in the conventional arm
suffered a vascular access failure or underwent at least one
vascular access procedure (time to first access event
HR¼ 1.88, 95% CI 0.97–3.64, P¼ 0.06, Figure 6). During
months 0–3, 3–6, 6–9, and 9–12, there were 14, 9, 5, and 6
interventions in the frequent nocturnal arm and 4, 7, 4, and 6
interventions in the conventional arm, respectively. There
were fewer recorded hypotensive events in the frequent
nocturnal arm, but no significant differences in the number
of laboratory results indicating the presence of either
hypokalemia or hypophosphatemia in the two trial arms.
DISCUSSION
The frequent nocturnal hemodialysis intervention did not
meet the prespecified criteria for statistical significance for
either coprimary composite outcome of death/LV mass or
death/PHC. Frequent nocturnal hemodialysis substantially
improved the control of hyperphosphatemia and of systolic
blood pressure, did not produce detectable improvements in
any of the remaining prespecified main secondary outcomes
relative to the three times per week group, and tended to
increase vascular access events. These results differ from the
FHN Daily Trial, as in that study there was a statistically
significant benefit of more frequent hemodialysis for both
coprimary outcomes. The other secondary outcome findings
and vascular access findings of the FHN Daily Trial were
similar to those found in this trial.16
Table 2 | Features of randomized interventiona
Conventional
hemodialysis (n=42)
Frequent nocturnal
hemodialysis (n=45)
Ratio of means (frequent
nocturnal vs conventional) P-value
Number of hemodialysis treatments per week 2.91±0.21 5.06±0.80 1.74 o0.001
Percent of expected treatments attendedb
480% 97.6 72.7 — o0.001
o65–80% 0 13.6 —
o65% 2.4 13.6 —
Time per dialysis session (min) 256±65 379±62 1.48 o0.001
Total dialysis time per week (h) 12.6±3.9 30.8±9.1 2.45 o0.001
Blood flow rate (ml/min) 350±49 262±61 0.75 o0.001
Dialysate flow rate (ml/min) 554±126 354±106 0.64 o0.001
Dialyzer urea clearance (ml/min) 236±26 181±30 0.77 o0.001
Ultrafiltration (weight change)
Per session (l) 2.52±1.01 1.95±0.66 0.77 0.003
Per session (% of post weight) 3.10±1.00 2.29±0.83 0.74 o0.001
Per week (l) 7.41±3.02 9.13±3.26 1.23 0.01
Kt/Vurea
Total weekly standard 2.91±0.86 5.03±1.23 1.73 o0.001
Dialysis weekly standard 2.59±0.69 4.72±1.18 1.82 o0.001
Equilibrated (per session) 1.48±0.5 1.87±0.8 1.26 0.009
Blood urea nitrogen (mg/dl)c
Before dialysis 54.8±13.0 38.5±9.8 0.70 o0.001
After dialysis 15.5±5.6 10.1±4.5 0.65 o0.001
Dialysate composition (initial concentration)
Sodium (mEq/l) 139±1 139±9 1.00 0.24
Potassium (mEq/l) 1.98±0.43 2.23±0.52 1.13 o0.001
Calcium (mEq/l) 2.61±0.25 2.89±0.37 1.11 o0.001
Use of buttonhole technique for access of arteriovenous fistulad 27.4% 45.5% — o0.001
aShown are either mean±s.d. or percentage for each baseline factor.
bIn the conventional group, 65 and 80% adherence represent an average of 1.95 and 2.40 treatments/week, and 3.9 and 4.8 treatments/week in the frequent nocturnal group.
cTo convert values for blood urea nitrogen (BUN) to mmol/l, multiply by 0.357.
dData on the type of cannulation were prospectively collected from July 2006 until the conclusion of the study.
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There are several possible explanations for the nonsigni-
ficant effects of the intervention on the coprimary end points,
some of which differ between the LV mass and PHC
outcomes.
First, the estimated treatment effect on the mean change
in LV mass (10.9 g) should be interpreted in the context
of its wide 95% CI (23.7 to þ 1.8). The CI contains the
value of 0, corresponding to no treatment effect. At the same
time, changes in LV mass close to the center of the interval
(for example, 10 g) have been associated with differences in
mortality of up to 50% in observational studies of dialysis
patients.17,18 Thus, when taken by themselves, the results of
the FHN Nocturnal Trial neither prove nor disprove the
hypothesis that frequent nocturnal dialysis leads to clinically
important reductions in LV mass. On the basis of the
dropout rates and variability in the change in LV mass
observed in the study, one would have needed a sample size
of 275 patients to obtain 80% power to detect a mean effect
on LV mass of 10 g, and 125 patients to detect a mean change
of 15 g.
Second, the FHN nocturnal LV mass results can be
interpreted in the context of previous studies. The FHN
nocturnal confidence interval contains the estimated effects
of the six times per week interventions in the recently
published FHN Daily Trial16 of 13.8 g (95% CI 21.8 to
5.8 g) and the shorter-term Culleton trial15 of 15.3 g (95%
CI 29.6 to 1.0 g). Hence, the differences between the
estimated effects on LV mass across the three randomized
trials of frequent hemodialysis are consistent with chance
variation. Given the positive effects on LV mass demonstrated
in the two previous randomized trials of frequent dialysis, the
inconclusive result of the FHN Nocturnal Trial could be
interpreted as consistent with the hypothesis that nocturnal
dialysis reduces LV mass to some extent. Although more
sophisticated statistical analyses may provide additional
hypothesis-generating information, the only method by
which this question can be properly answered is to perform
an adequately powered randomized clinical trial.
Finally, it is possible that differences in study population
or design may have contributed to differences between our
LV mass findings and those of the Culleton trial.15 The FHN
Nocturnal Trial included a larger proportion of incident
patients (B50%) than the Culleton trial. The median
duration of dialysis in the Culleton trial was 5.2 years
compared with 3.45 years in the FHN Nocturnal Trial.
Although the Culleton trial did not report residual renal
function, the difference in both the percentage of incident
patients and the mean duration of dialysis suggests that urine
volume and renal solute clearances are likely to have been
substantially larger in the FHN trial, thus reducing the
relative contribution of the dialysis regimens to total solute
and fluid removal. Design differences between the trials
include follow-up time (12 months in the FHN Nocturnal vs
6 months in the Culleton trial) and the method for
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measuring LV mass (which included papillary muscles in the
Culleton trial but not in the FHN Nocturnal Trial).
Both the conventional and frequent hemodialysis treat-
ments were performed primarily at home. The mean PHC
score for the entire FHN Nocturnal cohort (both frequent
nocturnal and conventional arms) increased by 2.4 points
(95% CI 0.3 to 4.5 points, P¼ 0.02). However, the increase in
the PHC score was similar between the two groups, with an
estimated mean difference of only 0.6 points, corresponding
to less thanB1/10th of the s.d. of PHC, with a 95% CI from
3.4 to 4.7 points (Table 3). Hence, although the overall
increase in the mean PHC in both treatment groups is
consistent with a positive effect of the change in venue from
in-center hemodialysis at baseline to home hemodialysis
during follow-up, our data provide no suggestion that the
PHC score was improved by the frequent dialysis therapy
itself. Although nocturnal dialysis has been reported to be
associated with improved quality of life in some previous
observational studies,11 our observation of an increase in the
PHC in both treatment arms suggests that these differences
may have resulted in part from differences in venue (home
for frequent nocturnal hemodialysis vs in-center hemodia-
lysis for conventional) rather than the therapy itself.
Adverse effects of more frequent nocturnal home
hemodialysis included a trend for more frequent vascular
access complications, which were due to an increase in
vascular access procedures other than failures. This observa-
tion is most likely secondary to the more frequent use of the
vascular access with more frequent hemodialysis. Hypo-
tensive episodes were less common in the frequent nocturnal
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arm, which could reflect either the lower ultrafiltration rates
used or differences in the reporting rates for hypotension
between the two study arms.
The strengths of the FHN Nocturnal Trial include the
relatively diverse patient population in terms of demo-
graphics and comorbidity, excellent separation between trial
arms for both weekly dialysis dose, as measured by stdKt/
Vurea, and the number of prescribed treatments per week, the
use of blinded cardiac magnetic resonance imaging measure-
ments for assessment of LV mass, and the wide variety of
secondary outcomes examined, including adverse events. In
contrast, previous observational studies have methodological
limitations, including selection bias, nonrandomized trial
study design, minimal data on access complications, and
other potential safety and feasibility issues.19
The major limitations of the trial were the relatively small
sample size and the lower adherence to the dialysis
prescription in the frequent nocturnal arm, both of which
reduced the power of the study. Recruitment was difficult as
the initial protocol forced random assignment to in-center
versus home hemodialysis; most patients interested in this
study uniformly wanted to be dialyzed at home. Recruitment
increased when patients were offered a choice between two
different types of home hemodialysis, but was still difficult in
part because of the proximity of other home hemodialysis
programs offering the use of new home hemodialysis
technologies and also because of barriers to acceptance of
home hemodialysis therapies.20 In addition, only 87.3% of
the patients who were randomized completed 12 months of
follow-up and had measures of both coprimary outcomes.
Moreover, B25% of patients in the frequent nocturnal arm
performed less than five hemodialysis treatments per week.
In addition, patients in the FHN Nocturnal Trial were
younger, had more residual renal function, and were less
likely to be African American,21 thus limiting generalizability
to the broader population of patients receiving maintenance
hemodialysis therapy. Finally, the trial was not powered to
determine the effect of the intervention on mortality or
hospitalization rate. Owing to difficulty in recruitment, the
power to detect modest differences in the coprimary
composite outcomes and the main secondary outcomes was
lower than anticipated.
Table 3 | Secondary outcomes
Observed data (Mean±s.d.) (patients with
non-missing baseline and follow-up values)
Main secondary analyses, controlling for
baseline value and pre-specified covariates
Outcome Treatment Na Baseline Follow-up
Change from
baseline to
follow-up
Adjusted mean
change from
baseline±s.e.
Treatment
comparison of
change: nocturnal
vs conventional
(95% CI) P-value
Left ventricular mass (g)b,c Conventional 39 132±41 133±42 0.6±24.9 1.7±4.5 10.9 (23.7, 1.8) 0.09
Nocturnal 37 141±48 132±55 8.2±31.7 9.2±4.6
Physical health compositeb Conventional 38 38.4±8.5 40.6±9.2 2.1±9.6 2.1±1.5 0.6 (3.4, 4.7) 0.75
Nocturnal 39 37.0±9.3 40.3±12.3 3.3±9.0 2.7±1.4
Beck depression inventoryb Conventional 38 11.7±9.3 11.1±10.2 0.6±9.6 0.4±1.3 1.5 (4.9, 1.9) 0.39
Nocturnal 39 11.8±7.9 9.7±8.6 2.1±5.2 1.9±1.2
Predialysis albumin (g/dl)b,d Conventional 39 3.93±0.53 4.12±0.38 0.19±0.46 0.19±0.06 0.02 (0.18, 0.15) 0.85
Nocturnal 37 3.88±0.49 4.08±0.53 0.20±0.41 0.18±0.06
Predialysis phosphorus (mg/dl)b,e Conventional 39 5.65±1.84 5.91±2.00 0.25±2.01 0.3±0.3 1.4 (2.1, 0.7) o0.001
Nocturnal 37 5.75±1.63 4.72±1.31 1.03±1.71 1.1±0.3
Erythropoiesis-stimulating agents Conventional 39 42,600±53,761 42,735±53,261 135±75,813 2±17% 1.35 (0.87, 2.09) 0.18
(EPO equivalent units)b,f Nocturnal 37 43,939±68,173 56,678±58,436 12,739±63,244 33±24%
Weekly average predialysis Conventional 39 153±22 151±19 1.9±16.0 0.1±2.6 9.7 (16.9, 2.5) 0.009
systolic BP (mmHg) Nocturnal 38 145±14 137±21 7.9±18.4 9.8±2.7
Number of prescribed Conventional 39 1.74±1.27 2.00±1.43 0.26±1.43 — — o0.001
antihypertensive agents Nocturnal 37 2.38±1.66 1.41±1.92 0.97±2.09 —
N patients (%) N patients (%) — — Risk ratio, nocturnal
vs conventional (95% CI)
P-value
Trail Making B Conventional 36 7 (19.4%) 8 (22.2%) — — 1.20 (0.52, 2.77) 0.66
(failure to complete in 5min)b Nocturnal 34 8 (23.5%) 8 (23.5%) — —
Non-access hospitalization
and deatha
Conventional 42 15 (38.1%) — 1.33 (0.67, 2.65) 0.42
Nocturnal 45 18 (40.0%) —
Abbreviation: EPO, erythropoietin.
aNumber of randomized patients for the non-access hospitalization/death outcome, and number of patients providing both baseline and follow-up measurements for the
remaining outcomes.
bPre-specified main secondary outcomes.
cWhen factored by body surface area per 1.73m2, the mean±s.d. baseline LV mass index was 118±31 g per 1.73m2 in the conventional group and 125±44 g per 1.73m2 in
the frequent nocturnal group.
dTo convert values for serum albumin to grams per liter, multiply by 10.
eTo convert values for phosphorus to millimoles per liter, multiply by 0.32.
fThe 12-month i.v. iron administration was significantly lower in the frequent nocturnal than the conventional group (exact stratified Wilcoxon P=0.007), with
median and 90th percentile levels of 100 and 250mg per month, respectively, in the frequent nocturnal group, and 200 and 425mg per month, respectively, in the
conventional group.
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In conclusion, frequent nocturnal home hemodialysis,
compared with three times per week hemodialysis, did not
result in significant benefits on the coprimary composite
outcomes of death/LV mass or death/PHC. Moderate effects
on LV mass may have gone undetected because of a small
sample size; PHC improved in both groups, perhaps
secondary to the effect of performing dialysis at home.
Frequent nocturnal hemodialysis improved control of
hyperphosphatemia and hypertension, but tended to increase
vascular access events.
MATERIALS AND METHODS
Study setting
The FHN Nocturnal Trial was a multicenter, randomized,
prospective trial of frequent home nocturnal hemodialysis spon-
sored by the National Institute of Health, National Institutes
Outcome Estimated standardized effects, 95% Cls
Favors conventional Favors nocturnal
LV mass
Physical health composite score
Beck depression inventory
Predialysis albumin
Predialysis phosphorus
ESA dose
Predialysis systolic BP
Trail making B
- Log HR
–1.0 –0.5 0.0
Standard deviation units
0.5 1.0
- Log RR
- Mean Δ
- Mean Δ
- Mean Δ
- Mean Δ
Effect measure
- Mean Δ
- Mean Δ
- Mean Δ log
Non-access hospitalization/death
Figure 5 |Main secondary results. The calculation of the standardized effect sizes is described in ref. 16.
BP, blood pressure; CI, confidence interval; ESA, erythropoiesis-stimulating agent; HR, hazard ratio; LV, left ventricular.
Table 4 | Adverse events
Outcome
Conventional
(n=42)a
Frequent
nocturnal (n=45)a
Hazard ratio
(95% confidence interval) P-value
Deaths 1 2
All hospitalizations 30 (16) 43 (19) 1.42 (0.69, 2.90) 0.34
Non-access hospitalizations 26 (15) 35 (17) 1.32 (0.60, 2.89) 0.48
Cardiovascular hospitalizations 4 (3) 6 (5) 1.60 (0.49, 5.22) —
Infection hospitalizations 7 (5) 14 (8) 2.04 (0.80, 5.17) —
Access hospitalizations 4 (3) 8 (5) 2.15 (0.67, 6.89) 0.20
All vascular access interventions 21 (15) 34 (23) 1.62 (0.91, 2.87) 0.10
Failures 13 (10) 17 (13) 1.27 (0.60, 2.71) 0.54
Other procedures 8 (6) 17 (12) 2.25 (0.87, 5.83) 0.095
Hypotensive episodes
Number of hypotensive episodes 136 (28) 71 (25) — —
Percent of dialysis treatments with a hypotensive episode 9.5 3.1 o0.001
Hypokalemia
Potassium o3.0mEq/l 0 8 (2) — 0.49
Potassium o3.5mEq/l 16 (9) 62 (13) — 0.47
Hypophosphatemia (phosphorus o2.17mg/dl)
Without phosphorus added to the dialysate 5 (3) 11 (10) — 0.071
With phosphorus added to the dialysate 4 (2) 6 (3) — 1.00
aIndicated are total numbers of events and (numbers of patients with events) during the follow-up period of the study.
Kidney International (2011) 80, 1080–1091 1087
MV Rocco et al.: Frequent home nocturnal hemodialysis o r ig ina l a r t i c l e
Diabetes, Digestive and Kidney Diseases (NIDDK), and the Center
for Medicare and Medical Services (CMS). The design of the FHN
Nocturnal Trial has been previously described.19,21 Patients were
enrolled between March 2006 and May 2009 and the trial concluded
in May 2010. The study was approved by the local institutional
review board at each participating site. An independent data safety
monitoring board provided oversight.
Study design
Study population. The inclusion and exclusion criteria are
listed in Supplementary Table S1 online. Written informed consent
was obtained from all participants.
Randomization. Patients were randomized in a 1:1 ratio to
either three times per week hemodialysis for o5 h per session
(conventional hemodialysis) or six times per week hemodialysis for
X6 h per session (frequent nocturnal hemodialysis). Randomization
was performed centrally using random permuted blocks, stratified
by clinical center and by diabetic status.
Interventions and follow-up. The weekly stdKt/Vurea was
defined as the ratio of urea generation rate to the average predialysis
urea concentration, adjusted for the number of hemodialysis
treatments per week.22 The delivered stdKt/Vurea was calculated by
formal urea kinetic modeling as the ratio of the urea generation rate
to the averaged predialysis blood urea nitrogen concentration with a
correction for residual renal function.23 Equilibrated eKt/V was
computed using a modified Tattersall correction to the single pool
Kt/V.24 The residual renal function exclusion criterion was higher in
the FHN Nocturnal Trial than in the FHN Daily Trial (410 ml/min
per 1.73 m2 as calculated as the average of the urea and creatinine
clearances versus 43 ml/min per 1.73 m2 of urea clearance,
respectively)21 as it was anticipated that the dose separation would
be greater in the Nocturnal Trial.
Patients in the conventional arm remained on their usual three
times per week hemodialysis prescription subject to a prescribed
eKt/Vurea 41.1, a stdKt/Vurea of 42.0, and a treatment timeX2.5 h/
session. Patients randomized to the frequent nocturnal arm followed
dialysis prescriptions subject to a stdKt/Vurea of X4.0 and a
treatment time ofX6 h, parameters designed to yield the maximum
feasible dose using current dialysis technology.
Treatment parameters were monitored while subjects remained
under the care of FHN centers. All treatment parameters were
averaged over the first modeled dialysis within each follow-up
month after 2 to 3 months. Adherence to the hemodialysis
prescription was calculated as the ratio of the number of delivered
hemodialysis treatments per month divided by the number of
prescribed hemodialysis sessions per month.
All study participants were dialyzed using single-use high-flux
dialyzers. A committee on standards of care, blinded to inter-
vention, periodically reviewed and reported to clinical centers
results of prespecified measures (phosphate, hemoglobin, bicarbo-
nate, normalized protein nitrogen appearance, and blood pressure
relative to achieved target postdialysis weight) that were outside
of values recommended in published guidelines. Demographic,
clinical, and laboratory data were obtained locally by site investi-
gators and study coordinators. Additional data on missed dialysis
sessions were obtained in both study arms on a prospective basis.
Detailed information on the delivered dialysis prescription was
obtained for all dialysis sessions that took place during 1 week of
each follow-up month. Standardized assessments of comorbidity
were obtained using a modification of the Charlson Index,25
supplemented by additional items from the Index of Co-existing
Disease Score.26
Outcomes
The two coprimary end points were: (1) death or 12-month
change in LV mass (death/LV mass), and (2) death or 12-month
change in the SF-36 RAND PHC (death/PHC).27 We stipulated
that demonstration of favorable effects on both coprimary outcomes
would be interpreted as providing evidence of overall benefit. LV
mass was measured by cardiac magnetic resonance imaging and
evaluated in a blinded manner by a central reading center.28
The SF-36 RAND PHC was obtained via blinded telephone
interviews conducted by a central quality of life core. Cost and
recruitment constraints precluded the possibility of examining
survival or hospitalization rates with adequate statistical power.
LV mass, however, has been shown to be an independent predictor
of survival,17 and studies in patients with end-stage renal disease18
have found that a decrease in LV mass over time is associated
with lower rates of death and cardiovascular events. In addition,
cross-sectional values of self-reported physical health in end-
stage renal disease patients correlate with mortality and hospitaliza-
tion rates.29
Nine conceptually distinct therapeutic outcome domains were
chosen to reflect the potential impact on multiple aspects of end-
stage renal disease. A single outcome measure was considered to be
the main secondary outcome for seven of these domains. These
included the change from baseline to 12 months in LV mass, PHC
score, Beck Depression Inventory,30 serum albumin, Trail Making
B,31,32 predialysis serum phosphorus level, and erythropoiesis-
stimulating agent dose. Other key secondary outcomes included the
rate of non-access hospitalization or death, and, for hypertension,
predialysis systolic blood pressure and the number of prescribed
antihypertensive agents.
Data regarding serious adverse events, including hospitalizations
and deaths, were collected prospectively and adjudicated in a
blinded manner by an outcomes committee. Vascular access events
were defined as access failures, infections requiring a procedure,
thrombectomies, angioplasties, catheter replacements, and fibrin
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Figure 6 | Time to first vascular access event. Shown are
Kaplan–Meier curves representing the conventional therapy
(black) and the frequent nocturnal (red) groups for the time from
randomization to each patient’s first access event, defined as an
access failure or other access procedure. CI, confidence interval;
HR, hazard ratio.
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stripping of catheters. Hypotensive episodes were defined as the
need for a lower ultrafiltration rate, reduced blood flow, or saline
administration to ameliorate hypotension. The investigators could
not be blinded to the patient’s assigned intervention; however,
investigators and patients remained blinded to outcome compar-
isons throughout the trial.
Vanguard design and protocol changes
Because the feasibility of conducting a randomized trial comparing
nocturnal home hemodialysis with conventional in-center hemo-
dialysis was not known, the trial was initially conducted using a
Vanguard design.33 Recruitment, retention, and adherence were
closely monitored during the initial year of the study to evaluate
viability of the sample size targets and delivery of the intervention.
Vanguard phase subjects were retained for final analyses.
During and after the Vanguard phase, several study design
parameters were changed. The original sample size of 250 patients
was estimated to provide 80% power to detect a 12-month change of
11.0 g in LV mass and a 4.2-point change in the SF-36 PHC. The
Vanguard phase of the trial revealed that this goal was not feasible,
and the target sample size was reduced to 150. The lower target
sample size was justified in part by newly published data15
suggesting that frequent nocturnal hemodialysis might reduce
average LV mass by B15 g, which could be detectable with slightly
fewer than 150 patients. However, the sample size was ultimately
reduced to 90 patients because of continued difficulties with
recruitment. This smaller sample size allowed for the detection of
only large effects in the two coprimary outcomes, with 80% power
to detect a 19.6-g reduction in LV mass and a 7.4-point
improvement in PHC.
In addition, the initial protocol specified that conventional arm
patients receive in-center hemodialysis three times a week. Follow-
up was 14 months to allow up to 2 months of in-center training
for the nocturnal home hemodialysis patients, resulting in at least
12 months of follow-up in the nocturnal arm. Because of the
difficulties with recruitment, a revised protocol was adopted in
which all of the last 72 participants were first trained in home
hemodialysis. Those patients randomized to the conventional arm
received hemodialysis at home rather than in-center hemodialysis.
Follow-up was also shortened to 12 months for the last 72 patients
randomized under the revised protocol; the 14-month follow-up
was retained for the first 15 patients.
Statistical analyses
The two coprimary composite outcomes were analyzed using the
Hochberg correction of the Bonferroni procedure,34 with a study-
wise two-sided significance level of 0.05. Each of the two coprimary
outcomes was analyzed using a rank-based nonparametric proce-
dure. Patients who had died were ranked lowest, with the order of
ranking determined by the duration of survival. Those who survived
were ranked based on the change in the LV mass (or PHC) from
baseline, with the ranking ordered from the most unfavorable
change to the most favorable change. Patients were right censored at
the time of transplantation or lost to follow-up; hence, patients who
survived but did not provide 1-year LV mass or PHC measurements
were credited with 1-year survival in the analysis. Ranks between the
treatment arms were compared using the log rank test, and Cox
regression was used to determine the associated HR and 95% CIs.
The analyses of the prespecified main secondary outcomes were
performed on a comparison-wise basis without adjustment for
multiple comparisons. Analyses of quantitative secondary outcomes
were performed on the observed data without imputation of missing
values by applying mixed-effects analyses using an unstructured
covariance model to account for correlations in measurements over
time,35 with covariate adjustment for age, diabetic status, baseline level
of the glomerular filtration rate, and the baseline variable under
analysis and the interactions of these factors with time. These models
were used to compare mean changes from baseline to month 12
between the treatment groups while incorporating values at baseline,
4 months (all but LV mass), and 12 months. The 4- and 12-month
values were averaged from three monthly assessments (months 3–5 and
10–12) for predialysis levels of albumin, phosphorus, hemoglobin, and
average weekly systolic blood pressure. In addition, treatment group
comparisons of unadjusted mean changes are provided for patients
completing their 12-month assessments for the LV mass and the PHC.
Certain modifications of this strategy were necessary for the
analyses of erythropoiesis-stimulating agents, the Trail Making B, and
the number of antihypertensive medications. Darbepoetin dose levels
were converted to approximate equivalent erythropoietin dose using
the expression erythropoietin dose (units)¼ 250 darbepoetin
(mg).36 The erythropoietin (or equivalent transformed darbepoetin)
dose was set to a minimum of 5000 units per 4 weeks for patients using
o5000 units, and log transformed before application of the mixed-
effects analysis described above. The treatment effect on erythro-
poiesis-stimulating agents was expressed as the ratio of the geometric
mean changes between the frequent nocturnal and conventional
groups. Standard errors of the adjusted means for erythropoiesis-
stimulating agents were computed using the d-method. Treatment
group comparisons for the number of antihypertensive agents and the
Trail Making B (with patients failing to complete the Trail Making B
assigned the lowest rank) were obtained using exact Wilcoxon rank-
sum tests stratified by quartiles of the corresponding baseline values.
Time to death, first non-access hospitalization/death, and first
access intervention were analyzed with Cox regression, controlling
for diabetes, age, and baseline glomerular filtration rate. HRs
and P-values comparing treatment arm event rates for multiple
hospitalizations and vascular access events per patient were calculated
using the Andersen–Gill model. Comparison of other adverse
events between the two treatment arms was made using Fisher’s
exact test. All analyses were performed according to intent-to-treat
principle and were performed using SAS version 9.2 (SAS Institute,
Cary, NC).
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